© 1999 American Heart Association, Inc.
Original Contribution |
Plasminogen Is Not Required for Neointima Formation in a Mouse Model of Vein Graft Stenosis
From the Cardiovascular Biology Laboratory (C.S., A.P., D.Z., H.W., G.L.R., M.-E.L., E.H., N.E.S.S.), Harvard School of Public Health, Boston, Mass; Department of Medicine (N.E.S.S., G.L.R., M.-E.L., E.H.), Harvard Medical School, Boston, Mass; Cardiovascular Division (N.E.S.S., M.E.-L.), Brigham and Women's Hospital, Boston, Mass; Cardiac Unit (G.L.R.), Massachusetts General Hospital, Boston, Mass; and the Center for Transgene Technology and Gene Therapy (P.C.), Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium.
Correspondence to Nicholas E.S. Sibinga, MD, Cardiovascular Biology Laboratory, Harvard School of Public Health, 677 Huntington Ave, Boston, MA 02115. E-mail sibinga{at}cvlab.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—Recent studies of mice that lack plasminogen have identified a critical role for this zymogen in arterial remodeling. To permit the use of these (and other) genetically modified mice in the analysis of venous injury, we developed a model in which a patch cut from the external jugular vein of a mouse is grafted to repair a surgically created defect in its carotid artery. In wild-type mice, the venous graft showed initial endothelial denudation and formation of a neointima that progressively and reproducibly expanded in a manner analogous to human vein graft disease, albeit at an accelerated pace. This neointima occupied 37±4.6% of the vessel lumen at day 7 and 66±5.7% at day 20. The proliferative index of neointimal cells assessed by proliferating cell nuclear antigen staining was 50.6±3.6% at day 7 and 15.2±2.0% at day 20. CD45-positive leukocytes and
-actin–positive smooth muscle cells accounted for 9.5±1.0% and
9.9±1.1% of intimal area at day 7, respectively, with the latter
increasing to 40.9±2.6% at day 20. Collagen accounted for 6.8±0.7%
of intimal area at day 7 and 20.7±1.8% at day 20. Surprisingly, even
though arterial neointima formation due to
electrostatic and immune-mediated injury is impaired in
plasminogen –/– mice, in our study vein graft
neointima formation in these mice was not significantly
different from that in controls (70.9±6.4 versus 65.6±4.4% luminal
occlusion, P=NS). Thus, plasmin proteolysis, although
critical in extracellular matrix degradation and cellular migration
after arterial injury, does not appear to be so important
in vein graft neointima formation, perhaps because of the
relative lack of structural barriers to cellular migration in the
normal vein wall. This novel model of vein graft injury should be
useful for further studies of differences in the response to injury of
arterial and venous tissues.
Key Words: bypass surgery • coronary disease • intimal hyperplasia • arteriosclerosis • gene knockout
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Coronary artery bypass surgery is the most effective means of revascularization for patients with multivessel coronary artery disease.1 2 3 Over the past decade, the number of patients undergoing coronary artery bypass grafting in the United States has continued to grow to nearly 500 000 per year,4 in spite of the development and dissemination of catheter-based revascularization techniques. Since the introduction of coronary artery bypass surgery in the 1960s, the major improvement to long-term outcome has stemmed from the increased use of arterial grafts, especially internal mammary arteries,5 rather than saphenous vein grafts. Nevertheless, in comparison with the internal mammary artery, the saphenous vein retains several practical advantages: it is relatively easy to harvest, yields abundant graft material for bypassing or reconstructing multiple vessels, and typically provides a conduit large enough to allow adequate flow to the bypassed vessel. These considerations ensure the continued application of the saphenous vein for coronary artery grafting,6 even though the internal mammary artery clearly provides better long-term results.
Unfortunately, the rate of saphenous vein graft failure remains high, despite significant refinements in surgical technique. Graft attrition (defined as loss of function) ranges from 8% to 12% in the first 4 weeks after surgery and climbs to at least 12% to 20% after 1 year.5 Up to 30% of vein grafts become stenotic and require intervention within 2 years because of the development of hemodynamically significant intimal hyperplastic lesions. By 10 years, the rate of closure may be as high as 50% because of the combined effects of thrombosis, intimal hyperplasia, and graft atherosclerosis. Patients with failed grafts frequently require repeat bypass surgery because of recurrent angina, congestive heart failure, or myocardial infarction.5 7
Failure of aortocoronary vein grafts can be attributed
primarily to 3 processes: thrombosis, intimal hyperplasia, and vein
graft atherosclerosis. When a graft fails in the first
few weeks after surgery, thrombosis is usually the reason. Intimal
hyperplasia, the most common pathological process leading to graft
failure overall, typically develops between 1 month and 5 years after
surgery. This process, reflecting exuberant smooth muscle cell growth,
happens to some degree in all grafts and provides the substrate for
subsequent development of graft atherosclerosis and
late thrombosis. Vein graft atherosclerosis may begin
as early as the first year after surgery but develops fully only after
5 years.5
Vein graft thrombosis and atherosclerosis have been the principal targets of a number of clinical trials, with some benefit reported for anti-platelet8 and lipid-lowering agents9 10 and little utility ascribed to anticoagulants.10 Despite its role in fostering both vein graft atherosclerosis and late thrombosis, the problem of intimal hyperplasia has not been addressed on a similar scale, perhaps because the available pharmacologic inhibitors of vascular smooth muscle cell proliferation have been disappointing in trials attempting to prevent restenosis after coronary angioplasty.11 These failures may in part reflect redundancies in the growth factor–mediated signaling pathways that promote smooth muscle cell migration and proliferation after arterial injury.
Although it has been proposed that mural thrombosis12 or an immune response13 is involved in the pathogenesis of vein graft intimal hyperplasia, there are indications that this phenomenon is also a response to injury. Indeed, the grafted vein is subjected to markedly altered mechanical stresses that affect the entire vessel wall.14 15 Changes in blood flow or shear stress may initiate changes in the function of the endothelium16 17 that in turn affect its interaction with blood cells or underlying smooth muscle cells. In addition, the deleterious effects of these stresses are probably exacerbated by differences between venous and arterial cells in intrinsic fibrinolytic capacity,18 lipid avidity,19 and response to pulsatile stress and growth factors.20 Nevertheless, the precise pathogenesis of vein graft disease remains obscure, because, although numerous changes in mechanical, humoral, and vascular cell factors that may contribute to the process have been identified, the hierarchical relationships among these factors are not well understood. The animal models currently available have not helped clarify the underlying molecular mechanisms of the disease.
A major opportunity, not yet explored, for defining the detailed pathogenesis of intimal hyperplasia and vein graft stenosis can now be found in the study of mice subjected to specific gene deletions. Although several models of arterial injury in the mouse have been developed,21 22 23 24 these models are not necessarily relevant to the study of venous injury. We have developed a model of vein graft stenosis in inbred mice that reproduces many of the features of human saphenous vein graft disease. In this model, a segment of jugular vein is used as an autografted patch to repair a surgically created defect in the mouse carotid artery. This procedure causes limited mural thrombosis in the vessel that receives the graft and yields substantial intimal hyperplasia in the vein patch in a rapid and highly reproducible fashion. Recent reports have indicated that plasmin, in addition to its importance in tumor cell migration and invasion, plays a critical role in several forms of vascular remodeling. This protease, derived from the zymogen plasminogen (Plg) through the activity of the tissue-type or urokinase-type Plg activators,25 has been implicated in arterial neointima formation after electrostatic26 and immune-mediated27 injury and in atherosclerotic aneurysm formation.28 When we applied our model of venous injury to mice genetically engineered to be deficient in Plg, however, we found no significant difference in the extent of vein patch neointima formation in comparison with control animals. The absence of an effect of Plg deficiency on vein graft neointima formation indicates that arterial and venous tissues differ significantly in the molecular physiology of their response to injury. We believe the vein patch model will provide a valuable tool for investigating the effect of specific gene deletions on intimal hyperplasia in vein grafts.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Mice
Four strains of inbred mice were studied, 3 wild type and 1 genetically modified (Plg –/–). Most of the surgery was performed on C57BL/6(H-2b) mice, also known as B6. We then extended the model to mice of mixed genetic backgrounds, applying it to B6/129(H-2b) mice (F1 generation) and B6/129(H-2b) mice backcrossed once with the B6 strain (F2 generation). These crosses allowed assessment of the dependence of neointima formation on the genetic contributions from the B6 strain, known for its tendency to develop arteriosclerosis, and from the 129 strain typically used to create genetically modified mice. The respective contributions of the 3 wild-type strains to the mice studied were C57BL/6(H-2b), or B6, 100%; F1 generation, 50% B6 and 50% 129; and F2 generation, 75% B6 and 25% 129.
A total of 36 male mice aged 7 to 12 weeks and weighing 25 to 30 g were used for these studies, 32 of wild-type strains and 4 of a Plg –/– strain.29 Beyond this age range, Plg –/– mice tend to become ill. Two wild-type B6/129 F1 mice died during surgery from complications due to anesthesia. Of the remaining 34, 16 were C57BL/6 mice, 5 were B6/129 F1 mice, 9 were B6/129 F2 mice, and 4 were B6/129 F2 Plg –/– mice. The Plg –/– mice and wild-type B6/129 F2 mice were siblings derived from matings of Plg +/– heterozygotes; genotypes were confirmed by Southern blotting of total DNA as described.29 Grafts performed on C57BL/6 mice were harvested at days 7 and 20 after surgery. Those done on the B6/129 F1 and F2 (Plg +/+ and –/–) generations were harvested at day 20. One C57BL/6 animal from the 7-day group was excluded from the analysis because of total graft occlusion by a thrombus, to bring the total study group to 33 animals.
Surgery
The operation was performed on anesthetized mice
under a dissecting microscope (model M3Z, Wild). The mouse was fixed in
a supine position with its neck extended. A midline incision was made
on the ventral side of the neck from the suprasternal notch to the
chin. The left external jugular vein was dissected and its side
branches were ligated with a 10-0 suture. A segment of jugular vein
(5 mm long) was transsected from the main trunk after ligation
at both ends with 8-0 sutures. This segment was trimmed into an oval
shape, inverted, and left in place. Contact between the instruments and
the vein graft was minimized throughout the procedure. The left
(ipsilateral) carotid artery was dissected from its bifurcation toward
the aortic arch as far as was technically possible. The artery was then
occluded with 2 microvascular clamps (8 mm long, ROBOZ Surgical
Instrument Co) at either end of the exposed segment. A longitudinal
defect in the carotid artery (of about the same length as the jugular
vein patch) was created between the 2 clamps by excising two thirds of
the exposed wall with scissors. The carotid artery defect was repaired
under x16 magnification by suturing the prepared autogenous jugular
vein patch into the carotid artery defect with an 11-0 continuous
suture around the margin of the patch (Figure 1
). After the vascular clamps had
been removed, the vein patch was inspected carefully for adequacy of
repair. The operative field was irrigated thoroughly with saline
solution, and the skin incision was closed with a 6-0 suture.
|
Histology and Morphology
The grafts, together with a short segment of the native carotid
artery, were harvested 7 or 20 days after surgery. The specimens were
cut at the center of the graft, and 1 portion was processed by paraffin
embedding or fixation in methyl Carnoy solution for 3 hours. The other
portion was fixed in 4% paraformaldehyde for 3 hours,
dehydrated in 30% sucrose for 48 hours, and embedded in medium (OCT
compound, Miles). Consecutive serial sections (5 µm) were cut
from the center of the graft to the proximal and distal ends at the
junction with the native carotid artery. Three sections from each of
the 2 portions, obtained at 225-µm intervals (equivalent to 45
sections) from the center to the end of the graft, were treated with
Verhoeff stain and subjected to quantitative morphological
analysis. Intimal area was determined and cell nuclei were
counted as described.22 The intima was defined as the
region between the internal elastic lamina and the lumen, and the
percentage luminal narrowing was calculated as 100x(difference between
area inside the internal elastic lamina and area of the lumen÷area
inside the internal elastic lamina). Paraffin sections were
immunostained as described22 30 with alkaline
phosphatase–conjugated anti–-smooth muscle actin antibody (Sigma;
20 µg/mL), rat anti-mouse CD45 antibody (PharMingen; 0.5 µg/mL),
rat anti-mouse CD31 (platelet endothelial cell
adhesion molecule 1 [PECAM-1]) antibody (Phar-Mingen; 10 µg/mL),
rat anti-mouse F4/80 antibody (Caltag; 1 µg/mL), anti–proliferating
cell nuclear antigen (PCNA) antibody (clone PC10, Oncogene Science; 3
µg/mL), and goat anti-mouse fibrin(ogen) antibody (Nordic
Immunology; 1:1600 dilution). The specificity of immunohistochemical
staining was confirmed in relevant tissue sections by omitting primary
antibodies.
Statistical Methods
Statistical analyses were performed on sets of
area measurement and nuclear counting data from 6 C57BL/6 mice at day 7
after surgery and 9 C57BL/6 mice at day 20 after surgery (1 section
taken 150 µm from the center of the graft from each animal for
each of the 2 data sets). Serial sections from the same sets of animals
were stained for PECAM-1, -actin, CD45, collagen, and PCNA and
assessed quantitatively for immunohistochemical
analyses.30 To study the uniformity of
neointima formation, we serially sectioned 20-day grafts
from 3 animals and assessed morphometry (in 5-µm sections) at
intervals of 225 µm from the center to the end of the graft. To
assess the effect of Plg expression on neointima formation,
we compared neointimal area and cell number data from
20-day grafts in wild-type mice and 4 Plg –/– (B6/129
F2) mice. Area (µm2) and
numerical data were expressed as mean±SEM. Data obtained at days 7 and
20 were analyzed by the unpaired t test, with
significance accepted at P<0.05. Analyses were
performed with Statview 4.1 software (Abacus Concepts).
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Surgery
To model venous injury in the mouse, we tried a number of strategies that included venous interposition grafting to the common carotid artery and creation of a shunt by end-to-side anastomosis from the common carotid artery to the external jugular vein. These approaches did not work, however, because of technical difficulties stemming from mismatches in vein and artery size. The vein patch strategy provided a way to avoid this mismatch. Figure 1
summarizes the surgical method we developed.
The total time from excision of the vein patch to complete repair
of the carotid artery defect was 40 minutes. Prominent pulsations
and distention of the patch were visible directly after release of the
vascular clamps. Two mice died intraoperatively from complications due
to anesthesia, and there were no postoperative deaths. The
overall success rate was 92% (33/36).
Control Mouse Strains
Morphology and Morphometry, Day 7
Seven days after surgery in the C57BL/6 mice, staining for the
endothelial cell marker CD31 (PECAM-1) was continuous
in the arterial portion of the composite vessel but
variable in the venous patch, suggesting partial denudation of the
venous endothelium at the time of grafting or soon
after exposure of the venous graft to the arterial
circulation (Figure 2A). A
neointima of 5 to 8 cell layers lined much of the venous
portion of the composite vessel, with scant spillover onto the
arterial wall. This neointima was most
prominent near the junction between the arterial tissue and
the venous graft (Figure 2B). Most of the cells in the newly
formed areas stained positive for -actin, which is
consistent with a smooth muscle cell phenotype (Figure 2C); the remnant of the original arterial media also
stained strongly for -actin.
|
In veins the internal elastic lamina is less clearly defined than in
arteries.31 It appears as a stippled line (Figure 2B and 2C, arrows) composed of the elastin fibers that in a
normal vein would be oriented primarily along the length of the vessel.
The medial area of the vein graft adjacent to the internal elastic
lamina stained strongly for collagen (Figure 2D). CD45-positive
mononuclear leukocytes were present in small number in the
neointima (Figure 2E) but were abundant in the
adventitia, particularly in the venous portion of the composite vessel.
Staining for F4/80 antigen indicated that many of these cells were
macrophages (data not shown). In addition, many of the
neointimal and adventitial cells were stained by the
anti-PCNA antibody, indicating active proliferation both of smooth
muscle cells in the neointima and of leukocytes in the
adventitia (Figure 2F). In 2 of 6 samples harvested 7 days after
surgery, moderately sized mural thrombi (fibrin deposits, as indicated
by anti-fibrin[ogen] antibody staining) were noted immediately
adjacent to the venous internal elastic lamina (data not shown); a
seventh sample harvested 7 days after surgery had an occlusive thrombus
and was not included in the analysis.
Morphology and Morphometry, Day 20
By day 20 after surgery in the C57BL/6 mice, PECAM-1 staining
appeared more continuous in the venous part of the composite vessel
than at day 7, consistent with
re-endothelialization of the vein graft (Figure 3A). The neointima was
exuberant and occupied the greater part of the area inside the original
margin of the venous internal elastic lamina. Circumferentially
oriented elastic laminae were prominent, consistent with a
progressive "arterialization" of the graft (Figure 3B and 3C, arrowhead). Moreover, -actin staining was visible
throughout the neointima, indicating that smooth muscle
cells formed the bulk of this lesion (Figure 3C). Interestingly,
neointima formed primarily in association with the venous,
but not the arterial, part of the composite vessel,
although both were subject to surgical manipulation (Figure 3B and 3C). Masson trichrome staining indicated the deposition of
collagen, extending from the presumed medial area into the basal layers
of the neointima (Figure 3D). CD45-positive
leukocytes persisted in the neointima, whereas the density
of the adventitial infiltrate decreased in comparison with that in day
7 samples (Figure 3E). Many neointimal cells stained
for PCNA, consistent with ongoing replication of smooth muscle
cells, whereas very few adventitial cells stained for PCNA, even in the
areas with residual leukocytes (Figure 3F). Areas that
corresponded to fibrin deposits at day 7 were occupied by smooth muscle
cells at day 20, and very little residual fibrin deposition, as
determined by anti-fibrin(ogen) antibody staining, was visible (data
not shown).
|
Uniformity of Neointima Formation
We evaluated variation in neointima formation
along the vessel axis by analyzing serial sections from the center to
the end of 3 grafts harvested 20 days after surgery. Through the center
portion, the cross-sectional area occupied by the neointima
was very consistent, with the calculated luminal narrowing in
the 60% to 65% range. Starting at 1350 µm from the graft
center, this percentage decreased gradually. The calculated luminal
narrowing was <40% toward the end of the patch, where grafted venous
tissue composed only a small part of the vessel circumference (Figure 4). Thus, the zone of
consistency extended along the vessel axis for >2 mm
in the central portion of the graft, allowing an ample supply of tissue
for morphometric and immunohistochemical analyses.
|
Effect of Genetic Background
To assess the possible influence of the mouse strain on
neointima formation, we performed surgery in mice of 3
genetic backgrounds: C57BL/6(H-2b), B6/129(H-2b)
F1 generation, and B6/129(H-2b)
F2 generation. The extent of
neointima formation at 20 days did not differ among these
strains, as calculated luminal narrowings were between 63% and 66%
for all 3 (Figure 5). Thus, within a
spectrum of genetic backgrounds that could be anticipated for use in
experiments with mouse lines generated by gene targeting,
neointima formation did not depend on strain.
|
Quantitative Analysis, Days 7 and 20
To evaluate neointima formation and content
quantitatively, we used an automated system for determining the area of
specific staining and cell number.30 The data are
summarized in the Table.
Neointimal cross-sectional area in wild-type mice increased
from 26 694±3726 µm2, corresponding to
37±5% of the lumen at day 7 after surgery to 96 039±7987
µm2, corresponding to 66±6% of the lumen at
day 20. Neointimal cell number increased from 357±44 on
cross section at day 7 to 953±109 at day 20. Overall, cell density
decreased modestly, from 13 891±1375
nuclei/µm2 at day 7 to 10 205±1147
nuclei/µm2 at day 20 (not shown).
-Actin–positive smooth muscle cells accounted for 9.9±1.1% of
intimal area at day 7 and 40.9±2.6% of intimal area at day 20
(Table). The number of smooth muscle cells on cross section
increased from 324±49 at day 7 to 910±104 at day 20 (not shown). Of
the cells present in the day 7 neointima, 50.6±3.6%
stained positive for PCNA (Table), consistent with
proliferation of both smooth muscle cells and leukocytes, whereas only
15.2±2.0% of the cells stained positive for PCNA at day 20.
|
The fraction of neointimal area occupied by CD45-positive
leukocytes in wild-type mice was <10% at days 7 (9.5%±0.1%) and 20
(4.5%±0.5%) (Table). Because CD45-positive cells accounted
for only 4.5±0.5% of the total cells at day 20, most of the
proliferating cells were probably smooth muscle cells, although it
would be difficult to exclude some proliferative activity of
fibroblasts or endothelial cells from the
analysis. At day 7, in spite of the presence of highly
proliferative smooth muscle cells in the neointima,
collagen staining accounted for only 6.8±0.7% of the intimal area. By
day 20, when the proliferative index had fallen by 70%, collagen
deposition had increased to 20.7±1.8% of the neointimal
area. Elastin fibrils were already present in the
neointima formed by day 7 after grafting and were quite
prominent at day 20. (Elastin staining could not be quantitated
automatically because Verhoeff stain colors both elastin material and
cellular nuclei black.32 )
Plg-Deficient Mice
After establishing that formation of neointima in the
vein patch was reproducible, amenable to quantitative analysis,
and not affected by genetic background, we applied the model to Plg
–/– mice. Recent studies in these mice indicate that Plg is important
for arterial remodeling in 2 distinct forms of
arterial injury, electrostatic26 and immune
system mediated.27 In venous injury in Plg –/– mice, in
contrast, we found no significant difference in neointima
formation between patches in Plg –/– and control animals at 20 days
after surgery (Figure 6). Although the
absence of Plg did not affect neointima formation, it was
associated with a higher proportion of CD45+
inflammatory cells (14.8±4.7 versus 4.5±0.5%, P=0.006;
Table). -Actin staining, cellularity (number of nuclei), and
cellular proliferation (percentage positive for PCNA) in Plg –/– mice
were not significantly different in comparison with controls at day 20
(Table).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The current understanding of the pathophysiology of vein graft disease derives from clinical observation, cell and organ culture, and animal models. Injury to the graft, beginning at the time of harvest, may initiate endothelial dysfunction that in turn promotes platelet adherence, activation, and thrombosis.33 Once implanted, the vein is subject to higher blood flow; greater longitudinal shear stress; and increased circumferential, radial, and pulsatile deformation and stress.17
These factors may impair venous endothelial function further and result in decreases in both nitric oxide and prostacyclin activity. Indeed, local intrinsic fibrinolytic activity in vein grafts is lower than in ungrafted veins,18 endothelium-dependent relaxation in human vein grafts is less than in nongrafted saphenous veins,34 and two thirds of the vein grafts removed during second coronary artery bypass operations show evidence of mural or occlusive thrombi.35
Impaired endothelial function may in turn affect smooth muscle cells by supporting proliferation and secretion of extracellular matrix: in cultured saphenous veins, removal of the endothelium or administration of agents that mimic the effect of prostacyclin or nitric oxide inhibits intimal smooth muscle cell proliferation,36 supporting a possible pathogenetic role for dysfunctional grafted venous endothelium.
Alternatively, some of these injurious forces may directly stimulate
smooth muscle cells. Venous smooth muscle cells proliferate more than
arterial smooth muscle cells in response to pulsatile
stretch and growth factors.20 On the basis of studies in a
rabbit model of vein grafting, it has been proposed that the
proliferative and synthetic response of smooth muscle cells continues
until tangential wall stress is normalized,14 suggesting a
regulatory mechanism intrinsic to the smooth muscle cell compartment.
In this model, cellular proliferation was highest 1 week after
grafting, with increased matrix accumulation accounting for
neointimal expansion at later time points,14
similar to cellular proliferation in our mouse vein patch model
(Table). Other studies in animals indicate the potential utility
of external vein graft stents, which appear to decrease tangential
stress in the rabbit37 and the pig.38
Antisense c-myb oligonucleotide applied to rabbit vein
grafts also inhibits intimal thickening,39 although the
mechanism responsible for this effect may not depend on the presumed
specificity of the oligonucleotide
sequence.40
The histologic changes we have observed in the mouse vein patch
model recapitulate vein graft intimal hyperplasia in an accelerated
fashion (Figure 6). The incidence of mural thrombosis and fibrin
deposition (see below), endothelial denudation and
regeneration (Figures 2A and 3A), and leukocyte
infiltration (Figures 2E and 3E) in the model appears to
fall within the spectrum of what has been reported for human vein
grafts. Two and four days after surgery, most of the vein patch grafts
showed small mural fibrin deposits without neointimal
thickening (data not shown). After 7 days, this thrombus deposition was
visible in only 20% of samples, and a neointima of up to 5
to 8 cell layers was typically present (Figure 2B). Staining
for fibrin at 20 days showed patchy deposits in the venous media and on
the lining of the vessel lumen. The endothelium was
discontinuous over the graft at 7 days but appeared largely regenerated
by 20 days (Figures 2A and 3A). Leukocytes composed
nearly 10% of the neointima at 7 days after grafting and
<5% at 20 days but persisted more in the adventitia (Figures 2E and 3E). Whereas the proliferative index fell from
50% of neointimal cells at 7 days after surgery to 15% by
20 days, collagen accumulated during this period, composing 20% of the
neointimal cross-sectional area at 20 days (Figure 3D). Elastin fiber formation was also apparent in the developing
neointima (Figure 3B and 3C). Consistent
with the increase in extracellular matrix components, cell density
decreased somewhat during this period. We believe that these events are
analogous to the first 2 stages of human vein graft disease, and we
speculate that by performing this procedure in
hyperlipidemic mice,41 42 we may be able
to reproduce the third phase of vein graft disease, graft
atherosclerosis.
Our work with the vein patch in Plg –/– mice underscores the need for
a mouse model of venous as opposed to arterial injury. In a
model of arterial injury, neointima formation
decreased significantly in Plg –/– mice.26
Neointima formation and fragmentation of medial elastic
laminae were also impaired in wild-type carotid arteries allografted
into Plg –/– mice in comparison with those grafted into Plg +/+
controls.27 In contrast, we found no significant
difference in overall neointima formation in vein patches
grafted into Plg –/– mice in comparison with vein patches grafted
into wild-type mice. We did find a modest increase in the proportion of
vein patch neointimal CD45+
inflammatory cells in Plg –/– mice, which suggests that the absence
of Plg may affect cellular trafficking in the vein graft, although not
to a degree that significantly affects neointima formation.
Arterial injury in Plg –/– mice was associated with a
lower proportion of inflammatory cells in the neointimal
cell population26 ; venous injury in Plg –/– mice
(Table) was associated with a higher proportion of
CD45+ leukocytes in the neointimal
cell population at 20 days after injury.
One explanation for these divergent results may lie in the
underlying structural differences between arteries and veins. Plasmin,
the active derivative of Plg, has been implicated in matrix degradation
and tissue remodeling via activation of matrix
metalloproteinases.28 In addition, plasmin can release
growth factor activities latent in the extracellular
matrix.43 44 The decrease in arterial
neointima formation in Plg –/– mice is thought to result
from impaired smooth muscle cell or leukocyte migration caused by an
inability to degrade surrounding matrix molecules, notably the elastic
laminae.26 27 Veins lack the developed internal elastic
lamina that is found in arteries.31 Our results indicate
that plasmin-mediated proteolysis may be less important in
neointima formation in veins than in arteries, possibly
because of a relative lack of preformed barriers to smooth muscle cell
and leukocyte migration in veins. Consistent with the
observations of Carmeliet et al26 in their model of
arterial injury in Plg –/– mice, we did not find a
significant deficit in neointimal cellular proliferation in
our model of venous injury in these same mice (relative to control
samples at day 20 [Table]).
We speculate that the higher proportion of leukocytes in Plg –/– vein graft neointimas at 20 days after injury may result from some impediment to leukocyte migration from the elastin-rich neointima, which develops rapidly in our model. Plg –/– leukocytes still express other proteinases that allow tissue infiltration in a Plg-independent manner, as long as the physical barriers are not too great. As the elastin and collagen content of the vein patch neointima increases after grafting, the limited proteolytic capacities of these leukocytes may be exceeded, in effect trapping the cells in the developing neointima.
Many questions remain about the precise relationships among the various mechanical, humoral, and cellular factors that contribute to vein graft disease. The utility of the vein patch model to investigators of the complex process of vein graft disease lies in its potential application in additional genetically modified mice that bear gene deletions affecting vascular or blood cell function. Through such investigations, we hope to define the regulatory mechanisms that link the various cell types and molecules in the vein graft wall.
|
Acknowledgments |
|---|
This work was supported by National Institutes of Health grants HL03274 (to N.E.S.S.), HL57314 (to G.L.R.), and GM53249 to (M.-E. L.) and by a grant from Bristol-Myers Squibb. We thank Thomas McVarish for editing the manuscript, Lester Kobzik for advice on immunohistochemistry, Drew Tenenholz for animal care and expertise, Mark Perrella for useful suggestions, Chung-Ming Hsieh for help with figure preparation, and Phobrek Taz for the illustration of the vein patch model. This work is dedicated to the memory of Edgar Haber.
|
Footnotes |
|---|
1 Deceased.
Received January 4, 1999; accepted February 1, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Alderman EL, Andrews K, Bost J, Bourassa M, Chaitman BR, Detre K, Faxon DP, Follmann D, Frye RL, Hlatky M, Jones RH, Kelsey SF, Rogers WJ, Rosen AD, Schaff H, Sellers MA, Sopko G, Tyrrell KS, Williams DO. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335:217–225.
2.
Zhao XQ, Brown BG, Stewart DK, Hillger LA, Barnhart
HX, Kosinski AS, Weintraub WS, King SB. Effectiveness of
revascularization in the Emory Angioplasty Versus
Surgery Trial: a randomized comparison of coronary angioplasty
with bypass surgery. Circulation. 1996;93:1954–1962.
3.
Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks
MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB.
Medical care costs and quality of life after randomization to
coronary angioplasty or coronary bypass surgery.
N Engl J Med. 1997;336:92–99.
4. National Center for Health Statistics. Quarterly Fact Sheet: Monitoring Health Care in America. Hyattsville, Md: National Center for Health Statistics; 1996.
5.
Nwasokwa ON. Coronary artery bypass graft
disease. Ann Intern Med. 1995;123:528–545.
6.
Angelini GD, Newby AC. The future of saphenous vein as
a coronary artery bypass conduit. Eur Heart J. 1989;10:273–280.
7. Davies MG, Hagen PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg. 1995;9:7–18.[Medline] [Order article via Infotrieve]
8. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR Jr, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Danielson GK, Schaff HV, Frye RL. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med. 1984;310:209–214.[Abstract]
9.
Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME,
Azen SP, Cashin-Hemphill L. Beneficial effects of combined
colestipol-niacin therapy on coronary
atherosclerosis and coronary venous bypass
grafts. JAMA. 1987;257:3233–3240.
10.
The Post Coronary Artery Bypass Graft Trial
Investigators. The effect of aggressive lowering of low-density
lipoprotein cholesterol levels and low-dose anticoagulation
on obstructive changes in saphenous-vein coronary-artery bypass
grafts. N Engl J Med. 1997;336:153–162.
11.
Kuntz RE, Baim DS. Defining coronary
restenosis: newer clinical and angiographic paradigms.
Circulation. 1993;88:1310–1323.
12.
Bulkley B, Hutchins G. Accelerated
"atherosclerosis": a morphologic study of 97
saphenous vein coronary artery bypass grafts.
Circulation. 1977;55:163–169.
13. Ratliff N, Myles J. Rapidly progressive atherosclerosis in aortocoronary saphenous vein grafts: possible immune-mediated disease. Arch Pathol Lab Med. 1989;113:772–776.[Medline] [Order article via Infotrieve]
14. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia: association with tangential stress. J Vasc Surg. 1987;5:126–136.[Medline] [Order article via Infotrieve]
15. Dobrin PB, Littooy FN, Endean ED. Mechanical factors predisposing to intimal hyperplasia and medial thickening in autogenous vein grafts. Surgery. 1989;105:393–400.[Medline] [Order article via Infotrieve]
16. Nagel T, Resnick N, Atkinson WJ, Dewey CF Jr, Gimbrone MA Jr. Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells. J Clin Invest. 1994;94:885–891.
17. Golledge J, Turner RJ, Harley SL, Springall DR, Powell JT. Circumferential deformation and shear stress induce differential responses in saphenous vein endothelium exposed to arterial flow. J Clin Invest. 1997;99:2719–2726.[Medline] [Order article via Infotrieve]
18. Risberg B. Fibrinolysis in grafted arteries and veins. Thromb Haemost. 1979;40:512–517.[Medline] [Order article via Infotrieve]
19. Fuchs JC. Lipid composition in venous arterial bypass grafts. Rev Surg. 1974;31:53–54.[Medline] [Order article via Infotrieve]
20. Yang Z, Luscher TF. Basic cellular mechanisms of coronary bypass graft disease. Eur Heart J. 1993;14(suppl I):193–197.
21.
Lindner V, Fingerle J, Reidy MA. Mouse model of
arterial injury. Circ Res. 1993;73:792–796.
22.
Shi C, Russell ME, Bianchi C, Newell JB, Haber E.
Murine model of accelerated transplant
arteriosclerosis. Circ Res. 1994;75:199–207.
23. Carmeliet P, Moons L, Stassen JM, Demol M, Bouche A, Vandenoord JJ, Kockx M, Collen D. Vascular wound healing and neointima formation induced by perivascular electric injury in mice. Am J Pathol. 1997;150:761–776.[Abstract]
24.
Kumar A, Lindner V. Remodeling with
neointima formation in the mouse carotid artery after
cessation of blood flow. Arterioscler Thromb Vasc Biol. 1997;17:2238–2244.
25. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res. 1998;91:255–285.[Medline] [Order article via Infotrieve]
26. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 1997;99:200–208.[Medline] [Order article via Infotrieve]
27. Moons L, Shi C, Ploplis V, Plow E, Haber E, Collen D, Carmeliet P. Reduced transplant arteriosclerosis in plasminogen deficient mice. J Clin Invest. 1998;102:1788–1797.[Medline] [Order article via Infotrieve]
28. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet. 1997;17:439–444.[Medline] [Order article via Infotrieve]
29.
Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen
I, Moons L, Plow EF, Collen D. Effects of disruption of the
plasminogen gene on thrombosis, growth, and health in mice.
Circulation. 1995;92:2585–2593.
30.
Shi C, Lee WS, He Q, Zhang D, Fletcher DL Jr, Newell
JB, Haber E. Immunologic basis of transplant-associated
arteriosclerosis. Proc Natl Acad Sci
U S A. 1996;93:4051–4056.
31. Cox JL, Chiasson DA, Gotlieb AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenosis with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis. 1991;34:45–68.[Medline] [Order article via Infotrieve]
32. Goodfellow BS, Mikat EM. A stain for the simultaneous demonstration of collagen, muscle, and elastic elements in mammalian tissue. Lab Med. 1988;19:243–244.
33. Davies MG, Hagen PO. Influence of perioperative storage solutions on long-term vein graft function and morphology. Ann Vasc Surg. 1994;8:150–157.[Medline] [Order article via Infotrieve]
34. Cross KS, Davies MG, el-Sanadiki MN, Murray JJ, Mikat EM, Hagen PO. Long-term human vein graft contractility and morphology: a functional and histopathological study of retrieved coronary vein grafts. Br J Surg. 1994;81:699–705.[Medline] [Order article via Infotrieve]
35. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation. 1988;78(suppl I):I-140–I-143.
36. Soyombo AA, Thurston VJ, Newby AC. Endothelial control of vascular smooth muscle proliferation in an organ culture of human saphenous vein. Eur Heart J. 1993;14(suppl I):201–206.
37. Kohler TR, Kirkman TR, Clowes AW. The effect of rigid external support on vein graft adaptation to the arterial circulation. J Vasc Surg. 1989;9:277–285.[Medline] [Order article via Infotrieve]
38.
Angelini GD, Izzat MB, Bryan AJ, Newby AC. External
stenting reduces early medial and neointimal thickening in
a pig model of arteriovenous bypass grafting. J Thorac
Cardiovasc Surg. 1996;112:79–84.
39. Fulton GJ, Davies MG, Koch WJ, Dalen H, Svendsen E, Hagen PO. Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts. J Vasc Surg. 1997;25:453–463.[Medline] [Order article via Infotrieve]
40.
Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX,
Bayewitch LA, Cohen AM, Herrera CJ, Hu SSF, Kramer TB, Lott FD, Martin
FH, Pierce GF, Simonet L, Farrell CL. The antiproliferative activity of
c-myb and c-myc antisense oligonucleotides in smooth
muscle cells is caused by a nonantisense mechanism. Proc Natl
Acad Sci U S A. 1995;92:4051–4055.
41.
Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R.
ApoE-deficient mice develop lesions of all phases of
atherosclerosis throughout the arterial
tree. Arterioscler Thromb. 1994;14:133–140.
42. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J Clin Invest. 1994;93:1885–1893.
43. Saksela O, Rifkin DB. Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol. 1988;4:93–126.
44. Matsushima K, Taguchi M, Kovacs EJ, Young HA, Oppenheim JJ. Intracellular localization of human monocyte associated interleukin 1 (IL-1) activity and release of biologically active IL-1 from monocytes by trypsin and plasmin. J Immunol. 1986;136:2883–2891.[Abstract]
This article has been cited by other articles:
 |
|
 |
|
  Y. Diao, S. Guthrie, S.-L. Xia, X. Ouyang, L. Zhang, J. Xue, P. Lee, M. Grant, E. Scott, and M. S. Segal Long-Term Engraftment of Bone Marrow-Derived Cells in the Intimal Hyperplasia Lesion of Autologous Vein Grafts Am. J. Pathol., March 1, 2008; 172(3): 839 - 848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schachner, G. Laufer, and J. Bonatti In vivo (animal) models of vein graft disease. Eur. J. Cardiothorac. Surg., September 1, 2006; 30(3): 451 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Schachner Pharmacologic inhibition of vein graft neointimal hyperplasia J. Thorac. Cardiovasc. Surg., May 1, 2006; 131(5): 1065 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sakaguchi, T. Asai, D. Belov, M. Okada, D. J. Pinsky, A. M. Schmidt, and Y. Naka Influence of ischemic injury on vein graft remodeling: Role of cyclic adenosine monophosphate second messenger pathway in enhanced vein graft preservation J. Thorac. Cardiovasc. Surg., January 1, 2005; 129(1): 129 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. B. Hotary, I. Yana, F. Sabeh, X.-Y. Li, K. Holmbeck, H. Birkedal-Hansen, E. D. Allen, N. Hiraoka, and S. J. Weiss Matrix Metalloproteinases (MMPs) Regulate Fibrin-invasive Activity via MT1-MMP-dependent and -independent Processes J. Exp. Med., January 28, 2002; 195(3): 295 - 308. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||